A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice.
hemoglobin detection
mass spectrometry
multiple reaction monitoring
sickle hemoglobin
viral vectors
β-globin
βAS3-globin
Journal
The journal of gene medicine
ISSN: 1521-2254
Titre abrégé: J Gene Med
Pays: England
ID NLM: 9815764
Informations de publication
Date de publication:
17 Jul 2023
17 Jul 2023
Historique:
revised:
16
06
2023
received:
07
04
2023
accepted:
26
06
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
aheadofprint
Résumé
Sickle cell disease (SCD) results from a sequence defect in the β-globin chain of adult hemoglobin (HbA) leading to expression of sickle hemoglobin (HbS). It is traditionally diagnosed by cellulose-acetate hemoglobin electrophoresis or high-performance liquid chromatography. While clinically useful, these methods have both sensitivity and specificity limitations. We developed a novel mass spectrometry (MS) method for the rapid, sensitive and highly quantitative detection of endogenous human β-globin and sickle hβ-globin, as well as lentiviral-encoded therapeutic hβAS3-globin in cultured cells and small quantities of mouse peripheral blood. The MS methods were used to phenotype homozygous HbA (AA), heterozygous HbA-HbS (AS) and homozygous HbS (SS) Townes SCD mice and detect lentiviral vector-encoded hβAS3-globin in transduced mouse erythroid cell cultures and transduced human CD34
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3567Subventions
Organisme : Midwest Athletes Against Childhood Cancer
Organisme : Caragher Family
Organisme : Greater Milwaukee Foundation
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4(1):18010. doi:10.1038/nrdp.2018.10
Marengo-Rowe AJ. Structure-function relations of human hemoglobins. Proc (Bayl Univ Med Cent). 2006;19(3):239-245. doi:10.1080/08998280.2006.11928171
Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180(4581):326-328. doi:10.1038/180326a0
Nagel RL, Johnson J, Bookchin RM, et al. β-Chain contact sites in the haemoglobin S polymer. Nature. 1980;283(5750):832-834. doi:10.1038/283832a0
Edelstein SJ, Telford JN, Crepeau RH. Structure of fibers of sickle cell hemoglobin. Proc Natl Acad Sci USA. 1973;70(4):1104-1107. doi:10.1073/pnas.70.4.1104
Benesch RE, Kwong S, Benesch R. The effects of alpha chain mutations cis and trans to the β6 mutation on the polymerization of sickle cell haemoglobin. Nature. 1982;299(5880):231-234. doi:10.1038/299231a0
Novelli EM, Gladwin MT. Crises in sickle cell disease. Chest. 2016;149(4):1082-1093. doi:10.1016/j.chest.2015.12.016
Barbarani G, Labedz A, Stucchi S, Abbiati A, Ronchi AE. Physiological and aberrant gamma-globin transcription during development. Front Cell Dev Biol. 2021;9:640060. doi:10.3389/fcell.2021.640060
Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11):e1915374. doi:10.1001/jamanetworkopen.2019.15374
Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia a molecular disease. Science. 1949;110(2865):543-548. doi:10.1126/science.110.2865.543
Hoyer JD, Scheidt RM. Identification of hemoglobin variants by HPLC. Clin Chem. 2005;51(7):1303-1304; author reply 1305. doi:10.1373/clinchem.2005.049577
Nair S. Potential pithfalls in using HPLC and its interpretation in diagnosing HbS. J Rare Dis Res Treat. 2018;3(3):9-12. doi:10.29245/2572-9411/2018/3.1161
Trent RJ. Diagnosis of the haemoglobinopathies. Clin Biochem Rev. 2006;27(1):27-38.
Howard J. Sickle cell disease: when and how to transfuse. Hematology am Soc Hematol Educ Program. 2016;2016(1):625-631. doi:10.1182/asheducation-2016.1.625
Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354-2363. doi:10.1182/blood-2009-05-221333
Agrawal RK, Patel RK, Shah V, et al. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014;30(2):91-96. doi:10.1007/s12288-013-0261-4
Badawy SM, Thompson AA, Liem RI. Beliefs about hydroxyurea in youth with sickle cell disease. Hematol Oncol Stem Cell Ther. 2018;11(3):142-148. doi:10.1016/j.hemonc.2018.01.001
Ali MA, Ahmad A, Chaudry H, et al. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020;92:11-18. doi:10.1016/j.exphem.2020.08.008
Bolanos-Meade J, Brodsky RA. Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Curr Opin Oncol. 2009;21(2):158-161. doi:10.1097/CCO.0b013e328324ba04
Kassim AA, Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol Oncol Stem Cell Ther. 2017;10(4):259-266. doi:10.1016/j.hemonc.2017.05.008
Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644. doi:10.1056/NEJM199406093302303
Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252-260. doi:10.1056/NEJMoa2031054
Esrick EB, Lehmann LE, Biffi A, et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med. 2021;384(3):205-215. doi:10.1056/NEJMoa2029392
Breda L, Casu C, Gardenghi S, et al. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients. PLoS ONE. 2012;7(3):e32345. doi:10.1371/journal.pone.0032345
Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294(5550):2368-2371. doi:10.1126/science.1065806
Negre O, Eggimann AV, Beuzard Y, et al. Gene therapy of the β-hemoglobinopathies by lentiviral transfer of the βA(T87Q)-globin gene. Hum Gene Ther. 2016;27(2):148-165. doi:10.1089/hum.2016.007
Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848-855. doi:10.1056/NEJMoa1609677
McCune SL, Reilly MP, Chomo MJ, et al. Recombinant human hemoglobins designed for gene therapy of sickle cell disease. Proc Natl Acad Sci U S A. 1994;91(21):9852-9856. doi:10.1073/pnas.91.21.9852
Levasseur DN, Ryan TM, Reilly MP, McCune SL, Asakura T, Townes TM. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin. J Biol Chem. 2004;279(26):27518-27524. doi:10.1074/jbc.M402578200
Levasseur DN, Ryan TM, Pawlik KM, Townes TM. Correction of a mouse model of sickle cell disease: lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood. 2003;102(13):4312-4319. doi:10.1182/blood-2003-04-1251
Wait R. Introduction to mass spectrometry. Methods Mol Biol. 1993;17:191-213. doi:10.1385/0-89603-215-9:191
Daniel YA, Turner C, Haynes RM, Hunt BJ, Neil Dalton R. Rapid and specific detection of clinically significant haemoglobinopathies using electrospray mass spectrometry-mass spectrometry. Br J Haematol. 2005;130(4):635-643. doi:10.1111/j.1365-2141.2005.05646.x
Lobitz S, Telfer P, Cela E, et al. Newborn screening for sickle cell disease in Europe: recommendations from a pan-European consensus conference. Br J Haematol. 2018;183(4):648-660. doi:10.1111/bjh.15600
Desiere F, Deutsch EW, King NL, et al. The PeptideAtlas project. Nucleic Acids Res. 2006;34(90001):D655-D658. doi:10.1093/nar/gkj040
UniProt C. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49(D1):D480-D489. doi:10.1093/nar/gkaa1100
Duvaud S, Gabella C, Lisacek F, Stockinger H, Ioannidis V, Durinx C. Expasy, the Swiss bioinformatics resource portal, as designed by its users. Nucleic Acids Res. 2021;49(W1):W216-W227. doi:10.1093/nar/gkab225
Sayers EW, Bolton EE, Brister JR, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2022;50(D1):D20-D26. doi:10.1093/nar/gkab1112
Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. Science. 1997;278(5339):873-876. doi:10.1126/science.278.5339.873
Regan RD, Fenyk-Melody JE, Tran SM, Chen G, Stocking KL. Comparison of submental blood collection with the Retroorbital and submandibular methods in mice (Mus musculus). J am Assoc Lab Anim Sci. 2016;55(5):570-576.
Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-8471. doi:10.1128/JVI.72.11.8463-8471.1998
Wang JC, Felizardo TC, Au BC, et al. Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J. 2013;10(1):240. doi:10.1186/1743-422X-10-240
Persons DA, Hargrove PW, Allay ER, Hanawa H, Nienhuis AW. The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood. 2003;101(6):2175-2183. doi:10.1182/blood-2002-07-2211
Huang J, Khan A, Au BC, et al. Lentivector iterations and pre-clinical scale-up/toxicity testing: targeting mobilized CD34+ cells for correction of Fabry disease. Mol Ther Methods Clin Dev. 2017;5:241-258. doi:10.1016/j.omtm.2017.05.003
Kurita R, Suda N, Sudo K, et al. Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS ONE. 2013;8(3):e59890. doi:10.1371/journal.pone.0059890
Vinjamur DS, Bauer DE. Growing and genetically manipulating human umbilical cord blood-derived erythroid progenitor (HUDEP) cell lines. Methods Mol Biol. 2018;1698:275-284. doi:10.1007/978-1-4939-7428-3_17
Wilber A, Tschulena U, Hargrove PW, et al. A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts. Blood. 2010;115(15):3033-3041. doi:10.1182/blood-2009-08-240556
McIver SC, Hewitt KJ, Gao X, et al. Dissecting regulatory mechanisms using mouse fetal liver-derived erythroid cells. Methods Mol Biol. 2018;1698:67-89. doi:10.1007/978-1-4939-7428-3_4
Wilkinson AC, Dever DP, Baik R, et al. Cas9-AAV6 gene correction of β-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat Commun. 2021;12(1):686. doi:10.1038/s41467-021-20909-x
Laskay UA, Lobas AA, Srzentic K, et al. Proteome digestion specificity analysis for rational design of extended bottom-up and middle-down proteomics experiments. J Proteome Res. 2013;12(12):5558-5569. doi:10.1021/pr400522h
Romero Z, Urbinati F, Geiger S, et al. β-Globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest. 2013;123(8):3317-3330. doi:10.1172/JCI67930
Urbinati F, Hargrove PW, Geiger S, et al. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Exp Hematol. 2015;43(5):346-351. doi:10.1016/j.exphem.2015.01.009
Sawado T, Halow J, Bender MA, Groudine M. The β-globin locus control region (LCR) functions primarily by enhancing the transition from transcription initiation to elongation. Genes Dev. 2003;17(8):1009-1018. doi:10.1101/gad.1072303
Schubeler D, Groudine M, Bender MA. The murine β-globin locus control region regulates the rate of transcription but not the hyperacetylation of histones at the active genes. Proc Natl Acad Sci U S A. 2001;98(20):11432-11437. doi:10.1073/pnas.201394698
Bender MA, Bulger M, Close J, Groudine M. β-Globin gene switching and DNase I sensitivity of the endogenous β-globin locus in mice do not require the locus control region. Mol Cell. 2000;5(2):387-393. doi:10.1016/s1097-2765(00)80433-5
Finehout EJ, Lee KH. An introduction to mass spectrometry applications in biological research. Biochem Mol Biol Educ. 2004;32(2):93-100. doi:10.1002/bmb.2004.494032020331
Daniel Y, Elion J, Allaf B, et al. Newborn screening for sickle cell disease in Europe. Int J Neonatal Screen. 2019;5(1):15. doi:10.3390/ijns5010015
Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol. 2010;149(1):35-49. doi:10.1111/j.1365-2141.2009.08054.x
Giardine BM, Joly P, Pissard S, et al. Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2021;49(D1):D1192-D1196. doi:10.1093/nar/gkaa959
Arishi WA, Alhadrami HA, Zourob M. Techniques for the detection of sickle cell disease: a review. Micromachines (Basel). 2021;12(5):519. doi:10.3390/mi12050519
Fitzhugh CD, Cordes S, Taylor T, et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood. 2017;130(17):1946-1948. doi:10.1182/blood-2017-03-772392
Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022;386(7):617-628. doi:10.1056/NEJMoa2117175
Cornetta K, Duffy L, Turtle CJ, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. Mol Ther. 2018;26(1):280-288. doi:10.1016/j.ymthe.2017.09.008
Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479-1493. doi:10.1056/NEJMoa1705342
Goyal S, Tisdale J, Schmidt M, et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022;386(2):138-147. doi:10.1056/NEJMoa2109167
Hsieh MM, Bonner M, Pierciey FJ, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 2020;4(9):2058-2063. doi:10.1182/bloodadvances.2019001330
Saleh AH, Rothe M, Barber DL, et al. Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease. Mol Ther Methods Clin Dev. 2023;28:262-271. doi:10.1016/j.omtm.2023.01.003
Tucci F, Galimberti S, Naldini L, Valsecchi MG, Aiuti A. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. Nat Commun. 2022;13(1):1315. doi:10.1038/s41467-022-28762-2
Khan A, Barber DL, Huang J, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun. 2021;12(1):1178. doi:10.1038/s41467-021-21371-5
Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010;467(7313):318-322. doi:10.1038/nature09328
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672. doi:10.1126/science.288.5466.669
Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010;363(20):1918-1927. doi:10.1056/NEJMoa1003548
Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-458. doi:10.1056/NEJMoa0805817